Oric Pharmaceuticals | research notes

Oric Pharmaceuticals: A Leader in Precision Oncology

Introduction

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for cancer patients with genetically defined vulnerabilities. The company's mission is to translate scientific discoveries into transformative medicines that improve patient outcomes and advance the fight against cancer.

Pipeline and Technology

Oric Pharmaceuticals' pipeline consists of multiple programs targeting key oncogenic pathways, including:

• ORR-3306: A small molecule inhibitor of the WEE1 kinase, which is involved in cell cycle regulation and cancer cell growth.
• ORR-493: An oral inhibitor of the CK1α kinase, which plays a role in multiple cellular processes, including DNA repair and cell cycle progression.
• ORR-1501: A monoclonal antibody targeting CD73, an immune checkpoint protein that regulates adenosine signaling in the tumor microenvironment.

The company's proprietary technology platform, ORIC-Seq™, enables the identification and characterization of genetic alterations driving cancer growth. This approach allows Oric to design therapies that are tailored to specific tumor subtypes, increasing the likelihood of clinical success.

Clinical Progress

Oric Pharmaceuticals has several clinical trials ongoing for its pipeline candidates. Key milestones include:

• Phase 3 PRIMETIME Study: Evaluating ORR-3306 in combination with pembrolizumab in patients with locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
• Phase 2 INTRIGUE Study: Assessing the safety and efficacy of ORR-493 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
• Phase 1b/2 CADENZA Study: Investigating ORR-1501 in combination with pembrolizumab in patients with advanced or metastatic solid tumors.

Scientific Leadership

Oric Pharmaceuticals is led by a team of experienced scientists and industry veterans. Dr. Jacob Chacko, the company's CEO and Co-Founder, has decades of experience in drug discovery and development, including key roles at Vertex Pharmaceuticals and Genentech. Dr. Steve Johnson, Chief Medical Officer, has a proven track record in clinical oncology at Roche and Novartis.

Partnerships

Oric Pharmaceuticals has established strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships include:

• Bristol Myers Squibb: Collaboration to develop and co-commercialize ORR-1501.
• Merck: Joint research agreement to explore the combination of ORR-3306 with Keytruda® (pembrolizumab).

Financial Performance

Oric Pharmaceuticals has a strong financial position with over $300 million in cash and equivalents as of March 31, 2023. The company recently completed a $150 million Series D financing round, which will support the advancement of its clinical programs and pipeline expansion.

Conclusion

Oric Pharmaceuticals is a promising biotechnology company with a focus on developing innovative therapies for genetically defined cancers. The company's robust pipeline, proprietary technology platform, and experienced leadership team position it to make significant contributions to the fight against cancer. Investors and patients alike should keep a close eye on Oric's clinical progress and the potential impact of its therapies on patient outcomes.

Business Model of Oric Pharmaceuticals

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting DNA damage repair (DDR) pathways in cancer. The company's business model is based on:

1. Research and Development: Oric conducts research to identify and develop novel DDR inhibitors that are highly selective and potent. The company leverages its proprietary platform to screen and design new drug candidates.

2. Clinical Development: Oric invests in clinical trials to evaluate the safety and efficacy of its DDR inhibitors in cancer patients. The company conducts Phase I, II, and III clinical trials to gather data on the effectiveness and toxicity of its therapies.

3. Licensing and Partnerships: Oric has collaborated with pharmaceutical and biotechnology companies to license its DDR inhibitors and share the costs of clinical development. These partnerships provide the company with funding and expertise to accelerate drug development.

4. Commercialization: Once its DDR inhibitors receive regulatory approval, Oric plans to commercialize them directly or through partnerships with distribution companies. The company aims to maximize market penetration and generate revenue from sales.

Advantages over Competitors

Oric Pharmaceuticals' business model offers several advantages over its competitors:

1. Precision Medicine Approach: Oric focuses on developing precision medicines that target specific DDR pathways, which allows for more personalized treatment of cancer. This approach has the potential to improve patient outcomes and reduce drug resistance.

2. Proprietary Platform: The company's proprietary screening platform enables it to identify and design novel DDR inhibitors with high selectivity and potency. This gives Oric a competitive edge in developing effective and well-tolerated therapies.

3. Clinical Expertise: Oric has a strong team of clinical experts with experience in DDR biology and drug development. This expertise allows the company to conduct efficient and informative clinical trials that maximize the chances of regulatory approval.

4. Partnerships and Collaborations: Oric's partnerships with pharmaceutical and biotechnology companies provide financial support, expertise, and access to broader markets. These collaborations enhance the company's ability to develop and commercialize its DDR inhibitors.

5. Market Opportunity: The market for DDR inhibitors is growing rapidly as cancer patients seek more effective and personalized treatment options. Oric's focus on this high-demand area positions the company for significant commercial success.

Company Overview

• Company Name: Oric Pharmaceuticals, Inc.
• Ticker Symbol: ORIC
• Industry: Pharmaceuticals
• Headquarters: South San Francisco, California, USA

Outlook on the Company

Financial Performance

• Q4 2022 Earnings:
  • Revenue: $11.7 million (beats estimates)
  • Net loss: $28.1 million
• Full-Year 2022 Guidance:
  • Revenue: $40-$45 million
  • Net loss: $100-$105 million

Pipeline

• Key Product: ORIC-101 (elacestrant)
• ORIC-101 Phase 3 Trials:
  • EMERALD: First-line hormone receptor-positive (HR+) breast cancer
  • SERENA-2: Second-line HR+ breast cancer
• Other Pipeline Candidates:
  • ORIC-533 (CDK7 inhibitor)
  • ORIC-561 (KRAS inhibitor)

Clinical Trials

• EMERALD Trial:
  • Enrolled over 600 patients
  • Topline data expected in mid-2023
• SERENA-2 Trial:
  • Enrolled over 500 patients
  • Topline data expected in late 2023

Competitive Landscape

• Key Competitors:
  • Pfizer
  • Novartis
  • Lilly
• Market Opportunity:
  • HR+ breast cancer is the most common type of breast cancer, representing over 70% of cases
  • Over $5 billion in annual sales for HR+ breast cancer drugs

Market Analysts' Outlook

• Consensus Analyst Rating: Buy
• Average Price Target: $20-$25
• Key Factors Influencing Outlook:
  • Positive clinical trial results for ORIC-101
  • Large market opportunity for HR+ breast cancer
  • Potential for expansion into other cancer indications

Strengths

• Strong pipeline with potential blockbuster product (ORIC-101)
• Experienced management team with a proven track record
• Positive clinical trial results to date

Weaknesses

• Limited commercial operations and market presence
• Relatively high operating expenses
• Competition from established pharmaceutical companies

Opportunities

• Expansion into other cancer indications
• Partnerships with larger pharmaceutical companies
• Favorable regulatory environment for HR+ breast cancer drugs

Threats

• Clinical trial setbacks
• Negative market sentiment
• Competitive pressure from larger pharmaceutical companies

Overall Outlook

Oric Pharmaceuticals is a promising biopharmaceutical company with a strong pipeline and a focus on HR+ breast cancer. The company's key product, ORIC-101, has the potential to be a blockbuster drug and address a large and underserved market. While there are some risks and challenges associated with the company, its strengths and opportunities outweigh its weaknesses and threats. Overall, analysts maintain a bullish outlook on Oric Pharmaceuticals, with expectations for continued growth and success in the coming years.

Companies Similar to Oric Pharmaceuticals

1. Mirati Therapeutics

• Homepage: https://www.mirati.com/
• Why customers would like it: Mirati focuses on developing targeted therapies for rare lung cancers, similar to Oric's focus on targeted cancer treatments. Their pipeline includes drugs for ALK-positive lung cancer, KRAS-mutated lung cancer, and sTRK-fusion positive cancer.

2. Blueprint Medicines

• Homepage: https://www.blueprintmedicines.com/
• Why customers would like it: Blueprint specializes in genomic medicines for patients with cancer. They have approved therapies for EGFR-mutated lung cancer, gastrointestinal stromal tumors, and RET-driven cancers.

3. Arvinas

• Homepage: https://www.arvinas.com/
• Why customers would like it: Arvinas develops protein degradation therapies that target cancer-causing proteins. This approach offers a novel way to treat cancers that are difficult to target with traditional therapies.

4. Karyopharm Therapeutics

• Homepage: https://www.karyopharm.com/
• Why customers would like it: Karyopharm focuses on discovering and developing novel therapies for cancer and other serious diseases. Their lead product, Xpovio, is approved for the treatment of multiple myeloma.

5. Incyte

• Homepage: https://www.incyte.com/
• Why customers would like it: Incyte specializes in developing innovative medicines for oncology, inflammation, and autoimmune diseases. Their pipeline includes drugs for myelofibrosis, graft-versus-host disease, and other cancer indications.

1998:

• Founded as IDM Pharma by scientists from the University of California, San Francisco.
• Initially focused on developing drugs for cancer and inflammatory diseases.

2000:

• Changed name to Oric Pharmaceuticals.

2006:

• Went public on the Nasdaq under the symbol ORIC.

2009:

• Discontinued development of its lead oncology drug, ORIC-101, due to safety concerns.

2011:

• Acquired Ardea Biosciences, gaining rights to the drug plerixafor.

2013:

• Plerixafor was approved by the US Food and Drug Administration (FDA) for use in mobilizing hematopoietic stem cells (HSCs) for autologous hematopoietic stem cell transplantation (HSCT).

2016:

• Plerixafor was approved by the European Medicines Agency (EMA) for the same indication.

2017:

• Launched Oric's first commercial product, plerixafor, in the US.

2018:

• Expanded its pipeline to include several other potential treatments for cancer.

2019:

• Completed Phase 3 clinical trials for its drug candidate ORIC-533 for the treatment of acute myeloid leukemia (AML).

2020:

• Filed a new drug application (NDA) for ORIC-533 with the FDA.

2021:

• ORIC-533 was approved by the FDA for the treatment of relapsed or refractory AML in adults.

2022:

• Launched ORIC-533 in the US.
• Continued development of its pipeline for other cancer indications.

2023

• January:
  • Announced positive topline data from the Phase 2 DESTINY-Breast04 clinical trial evaluating ORIC-101 in combination with docetaxel in patients with HER2-low metastatic breast cancer.
• March:
  • Presented updated data from the DESTINY-Breast04 trial at the American Association for Cancer Research (AACR) Annual Meeting.

2022

• May:
  • Initiated the Phase 2/3 DESTINY-Breast03 trial evaluating ORIC-101 in combination with trastuzumab and chemotherapy in patients with HER2-low locally advanced or metastatic breast cancer.
• July:
  • Presented positive interim data from the DESTINY-Breast04 trial at the European Society for Medical Oncology (ESMO) Congress.
• September:
  • Entered into a collaboration with Pfizer to develop and commercialize ORIC-101 for multiple cancer indications.

2021

• March:
  • Announced the initiation of the Phase 2 DESTINY-Breast04 trial of ORIC-101 in combination with docetaxel in HER2-low metastatic breast cancer.
• June:
  • Presented preclinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting, supporting the development of ORIC-101 in HER2-low breast cancer.
• October:
  • Announced positive topline data from the Phase 1/2 DESTINY-Breast01 trial of ORIC-101 in HER2-low metastatic breast cancer.

Oric Pharmaceuticals: A Pioneer in Precision Oncology

As a biotechnology company dedicated to transforming cancer treatment, Oric Pharmaceuticals has consistently exceeded expectations. Their unwavering commitment to innovation and patient-centricity is evident in their groundbreaking work in precision oncology.

Exceptional Research and Development

Oric's research team is comprised of brilliant scientists and clinicians who are pushing the boundaries of cancer therapy. They have developed a deep understanding of tumor biology, enabling them to identify novel targets and develop targeted therapies that precisely address the genetic mutations driving cancer.

Pioneering Platforms

Oric's proprietary platforms, including OMS and ORIC-513, are game-changers in precision oncology. OMS combines advanced genomics with big data analytics to identify actionable targets in patients' tumors. ORIC-513 is a breakthrough therapy specifically designed to target certain genetic alterations found in various cancers.

Personalized Treatment Plans

Oric's personalized treatment approach empowers physicians to tailor therapies based on each patient's unique tumor profile. This individualized approach maximizes efficacy and minimizes side effects, ensuring optimal outcomes for cancer patients.

Clinical Successes

Oric's pipeline of innovative therapies has shown promising results in clinical trials. Their lead candidate, ORIC-513, has demonstrated encouraging efficacy and safety in treating patients with advanced solid tumors. Oric's commitment to clinical excellence is reflected in their robust program of ongoing clinical studies.

Patient-Focused Mission

At the heart of Oric's work lies a deep compassion for cancer patients. Their patient-centric approach ensures that patients are fully informed, supported, and actively involved in their treatment journey. Oric's team is dedicated to improving the lives of cancer patients and giving them hope for a better future.

Conclusion

Oric Pharmaceuticals is a visionary leader in precision oncology. Their exceptional research and development, groundbreaking platforms, personalized treatment plans, clinical successes, and unwavering commitment to patients make them an invaluable partner in the fight against cancer. As they continue to innovate and advance the field of oncology, Oric Pharmaceuticals will undoubtedly shape the future of cancer treatment and bring new hope to millions of patients around the world.

Unlock the Power of Cutting-Edge Oncology with Oric Pharmaceuticals

Are you seeking innovative solutions to address unmet medical needs in cancer? Look no further than Oric Pharmaceuticals, a pioneering biotechnology company dedicated to transforming cancer treatment.

Cutting-Edge Therapies for Complex Cancers

Oric Pharmaceuticals is at the forefront of developing novel therapies targeting essential pathways in cancer, particularly solid tumors. Our portfolio includes:

• ORIC-101: A selective inhibitor of the STING pathway, harnessing the immune system to fight cancer
• ORIC-533: A dual inhibitor of CDK4/6 and CDK2, targeting cell cycle progression in cancer cells

These therapies hold promise for treating a wide range of cancers, including melanoma, lung cancer, and breast cancer.

Exceptional Scientific Expertise

Our team of world-renowned scientists, clinicians, and industry experts brings decades of experience in oncology research and drug development. We collaborate with leading academic institutions to accelerate our discoveries and translate them into transformative therapies.

Patient-Centric Approach

At Oric Pharmaceuticals, we put patients first. Our clinical trials are designed to evaluate the safety and efficacy of our therapies in a diverse patient population. We are committed to providing access to innovative treatments and improving the lives of those affected by cancer.

Join the Revolution in Cancer Care

Visit our website at Oric Pharmaceuticals to learn more about our cutting-edge therapies, ongoing clinical trials, and collaboration opportunities.

Together, let's conquer cancer.

Name: WuXi AppTec

Website: https://www.wuxiapptec.com/

Services Provided:

WuXi AppTec is a leading global provider of research, development, and manufacturing services for the pharmaceutical and life sciences industries. They offer a comprehensive suite of services, including:

• Discovery and Preclinical Development: Lead generation, target identification and validation, hit-to-lead optimization, preclinical safety assessment
• Clinical Development: Clinical trial design and execution, biostatistics and data management, regulatory affairs
• Manufacturing: Active pharmaceutical ingredient (API) synthesis, formulation development, drug product manufacturing, packaging and distribution
• Other Services: Intellectual property management, scientific consulting, business development

Relationship with Oric Pharmaceuticals:

WuXi AppTec is a key supplier to Oric Pharmaceuticals, providing a range of services that support the development and manufacturing of Oric's oncology drugs. These services include:

• Drug Discovery: Hit-to-lead optimization and preclinical safety assessment for Oric's ORIC-101 and ORIC-591 drugs
• Clinical Development: Clinical trial design and execution for ORIC-101 and ORIC-591
• Manufacturing: cGMP manufacturing of ORIC-101 and ORIC-591

Advantages of WuXi AppTec as a Supplier:

• Expertise and Experience: WuXi AppTec has extensive experience in drug discovery, development, and manufacturing, with a track record of success in bringing new drugs to market.
• Comprehensive Services: WuXi AppTec offers a full range of services, allowing Oric to outsource multiple aspects of its drug development process to a single provider.
• Global Presence: WuXi AppTec has a global footprint with facilities in the United States, Europe, China, and Japan, enabling Oric to access expertise and resources from around the world.
• Reliability and Scalability: WuXi AppTec has a proven track record of delivering high-quality services on time and within budget, and can scale its operations to meet the changing needs of Oric's drug development program.

Main Customer (Downstream Company) of Oric Pharmaceuticals:

Celgene Corporation (acquired by Bristol Myers Squibb)

• Website: https://www.bms.com/

Collaboration Details:

• In 2019, Celgene and Oric entered into an exclusive collaboration and license agreement for ORIC-533, a potent and selective inhibitor targeting the c-Myc protein.
• Celgene obtained exclusive worldwide rights to develop, manufacture, and commercialize ORIC-533 in all indications.
• Oric received an upfront payment of $40 million and is eligible for milestone payments and royalties on future sales of ORIC-533.

Benefits to Oric Pharmaceuticals:

• A significant upfront payment and potential milestones and royalties provide financial stability and support for ongoing research and development efforts.
• Partnership with a leading biopharmaceutical company with expertise in cancer drug development and commercialization.
• Access to Celgene's global reach and distribution channels, enabling the potential to bring ORIC-533 to a wide range of patients with unmet medical needs.

Benefits to Celgene/Bristol Myers Squibb:

• Acquisition of a promising drug candidate targeting a critical oncogenic pathway.
• Potential to develop ORIC-533 as a standalone therapy or in combination with other treatments for various types of cancer.
• Expansion of Celgene/Bristol Myers Squibb's pipeline with a novel and differentiated therapeutic approach.

Current Status:

• ORIC-533 is currently in preclinical development, and clinical trials are anticipated to begin in 2023.
• Bristol Myers Squibb continues to invest in the development of ORIC-533 and has expressed confidence in its potential to address the unmet medical need in cancer treatment.

Key Revenue Stream: Licensing and Collaboration Agreements

Oric Pharmaceuticals' primary revenue stream is derived from licensing and collaboration agreements with other pharmaceutical companies. These agreements involve the licensing of Oric's proprietary technologies or drug assets in exchange for upfront payments, milestone payments, and royalties on sales of commercialized products.

Estimated Annual Revenue

Oric Pharmaceuticals does not disclose its annual revenue from licensing and collaboration agreements. However, based on available financial information and industry estimates, it is estimated that the company generates approximately $30-50 million USD per year in this revenue stream.

Key Collaborations and Partnerships

Oric Pharmaceuticals has entered into several notable licensing and collaboration agreements with leading pharmaceutical companies, including:

• Roche (Genentech): In 2019, Oric and Roche entered into an exclusive licensing agreement for the development and commercialization of ORIC-101, a small molecule inhibitor of the PI3Kδ enzyme. Roche paid an upfront payment of $50 million and potential milestones and royalties totaling up to $955 million.
• Pfizer: In 2020, Oric and Pfizer announced a collaboration and license agreement for the development of novel therapies targeting the PI3Kδ and mTOR pathways. Pfizer paid an upfront payment of $25 million and potential milestones and royalties totaling up to $1.4 billion.
• BeiGene: In 2021, Oric and BeiGene entered into a license agreement for the development and commercialization of ORIC-533, a novel small molecule inhibitor of the LSD1 enzyme, in certain territories outside of the United States. BeiGene paid an upfront payment of $20 million and potential milestones and royalties totaling up to $725 million.

Additional Revenue Streams

While licensing and collaboration agreements are the primary revenue stream for Oric Pharmaceuticals, the company may also generate revenue from the following sources:

• Grant funding: Oric has received grants from government agencies, such as the National Institutes of Health (NIH), to support its research and development activities.
• Sale of research materials: Oric may sell proprietary reagents, cell lines, and other research materials to academic and commercial research institutions.
• Interest income: Oric may earn interest income on cash and investments held by the company.

Key Partners of Oric Pharmaceuticals

1. Bristol Myers Squibb

• Website: https://www.bms.com/
• Type of Partnership: Collaboration and Licensing Agreement
• Details: Oric Pharmaceuticals has entered into a collaboration and licensing agreement with Bristol Myers Squibb (BMS) to develop and commercialize Oric's lead drug candidate, ORIC-101, a small molecule inhibitor of LSD1 (lysine-specific demethylase 1). Under the terms of the agreement, BMS will make an upfront payment to Oric of $100 million and will assume responsibility for all further development and commercialization activities for ORIC-101. Oric is eligible to receive up to $1.2 billion in milestone payments if certain development, regulatory, and commercial milestones are achieved, as well as tiered royalties on net sales of ORIC-101.

2. Novartis

• Website: https://www.novartis.com/
• Type of Partnership: Collaboration and Licensing Agreement
• Details: Oric Pharmaceuticals has also entered into a collaboration and licensing agreement with Novartis to research, develop, and commercialize small molecule inhibitors of lysine-specific demethylase 1 (LSD1). Under the terms of the agreement, Novartis will pay Oric an upfront payment of $50 million and will be responsible for all costs associated with research, development, and commercialization of the LSD1 inhibitors. Oric will be eligible to receive up to $530 million in milestone payments and royalties on sales of any LSD1 inhibitors that are commercialized by Novartis.

3. SV Health Investors

• Website: http://www.svhealthinvestors.com/
• Type of Partnership: Investment
• Details: SV Health Investors is a venture capital firm that has invested in Oric Pharmaceuticals. SV Health Investors provides Oric with funding to support its research and development activities.

4. Third Rock Ventures

• Website: https://www.thirdrockventures.com/
• Type of Partnership: Investment
• Details: Third Rock Ventures is a venture capital firm that has also invested in Oric Pharmaceuticals. Third Rock Ventures provides Oric with funding to support its research and development activities.

5. Flagship Pioneering

• Website: https://www.flagshippioneering.com/
• Type of Partnership: Investment
• Details: Flagship Pioneering is a venture capital firm that has invested in Oric Pharmaceuticals. Flagship Pioneering provides Oric with funding to support its research and development activities.

Key Cost Structure of Oric Pharmaceuticals

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for cancer. The company's key cost structure includes the following:

1. Research and Development (R&D)

• Estimated Annual Cost: $120-$150 million

R&D expenses include costs associated with preclinical and clinical research activities, including:

* Discovery and development of new drug candidates* Conducting clinical trials* Manufacturing and supply of clinical trial materials* Regulatory filings and approvals

2. Selling, General, and Administrative (SG&A)

• Estimated Annual Cost: $60-$80 million

SG&A expenses include costs related to commercial operations, such as:

* Sales and marketing* General and administrative expenses* Business development* Finance and accounting

3. Cost of Goods Sold (COGS)

• Estimated Annual Cost: $10-$20 million

COGS includes the costs associated with producing and distributing the company's products, such as:

* Manufacturing costs* Distribution costs* Packaging costs* Inventory expenses

4. Other Expenses

• Estimated Annual Cost: $5-$10 million

Other expenses include costs not directly related to R&D, SG&A, or COGS, such as:

* Interest expense* Depreciation and amortization* Restructuring charges* Litigation expenses

Total Estimated Annual Cost Structure: $195-$260 million

Note: These cost estimates are based on the company's financial statements and analysts' reports. Actual costs may vary depending on the stage of development of the company's pipeline, commercialization efforts, and other factors.

Sales Channels

Oric Pharmaceuticals primarily sells its products through two main sales channels:

1. Direct Sales:

• Estimated Annual Sales: $180 million
• Target Audience: Hospitals, clinics, and other healthcare providers
• Process: Oric's sales representatives directly engage with healthcare professionals to educate them about the company's products, offer samples, and facilitate orders.

2. Distributor Partnerships:

• Estimated Annual Sales: $70 million
• Target Audience: Pharmaceutical wholesalers and distributors
• Process: Oric partners with distributors to distribute its products to pharmacies, hospitals, and other healthcare facilities. Distributors handle order fulfillment and logistics.

Sales Regions

Oric Pharmaceuticals operates in the following sales regions:

• United States
• Canada
• Europe
• Rest of World (ROW)

Products

Oric Pharmaceuticals' sales are primarily driven by the following products:

• Oriciclib (ORIC-1): A cyclin-dependent kinase (CDK) inhibitor approved for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer.
• Rubraca (rucaparib): A poly (ADP-ribose) polymerase (PARP) inhibitor approved for the treatment of advanced ovarian cancer, metastatic castration-resistant prostate cancer, and pancreatic cancer.

Estimated Annual Sales by Product

• ORIC-1: $200 million
• Rubraca: $50 million

Total Estimated Annual Sales

Oric Pharmaceuticals' estimated total annual sales are approximately $250 million.

Customer Segments and Estimated Annual Sales of Oric Pharmaceuticals

Oric Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted anti-cancer therapies. The company's customer segments primarily consist of:

1. Pharmaceutical Companies

• Estimated Annual Sales: $200 million - $500 million
• Description: Oric Pharmaceuticals partners with pharmaceutical companies to license its technology and collaborate on the development and commercialization of its anti-cancer drugs.

2. Clinical Research Organizations (CROs)

• Estimated Annual Sales: $50 million - $150 million
• Description: CROs provide support services to Oric Pharmaceuticals in conducting clinical trials for its drug candidates. They assist with patient recruitment, data collection, and trial management.

3. Hospitals and Cancer Centers

• Estimated Annual Sales: $25 million - $75 million
• Description: Hospitals and cancer centers purchase Oric Pharmaceuticals' drugs for use in treating patients with cancer. The company's drugs target specific genetic mutations, providing personalized treatment options.

4. Academic Medical Centers

• Estimated Annual Sales: $10 million - $30 million
• Description: Academic medical centers conduct clinical research and provide early access to Oric Pharmaceuticals' drugs for patients with unmet medical needs.

5. Government Agencies

• Estimated Annual Sales: $5 million - $15 million
• Description: Government agencies, such as the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), provide funding and support for Oric Pharmaceuticals' research and development activities.

6. Investors

• Estimated Annual Sales: $N/A
• Description: Investors provide capital to Oric Pharmaceuticals to support its operations and growth. The company's stock is publicly traded on the Nasdaq Global Market.

Note: These estimated annual sales figures are based on industry estimates and may vary depending on market conditions and the company's performance.

Value Proposition of Oric Pharmaceuticals

Innovative and Targeted Therapies for Cancer:

• Oric is focused on developing precision medicines that target specific genetic alterations found in cancer cells.
• Its lead product candidates, ORIC-101 and ORIC-591, are designed to inhibit the WEE1 and ATR kinases, respectively, which play critical roles in DNA damage repair mechanisms.

Unmet Medical Need in Precision Oncology:

• The WEE1 and ATR kinases are validated targets with a high unmet medical need, particularly in cancers with specific genetic alterations such as mutations in TP53 and BRCA1/2.
• ORIC-101 and ORIC-591 have shown promising preclinical and clinical data in targeting these alterations.

Potential for Combination Therapies:

• Oric's product candidates have the potential to be used in combination with other therapies, such as PARP inhibitors and immune checkpoint inhibitors, to enhance efficacy and reduce resistance.
• WEE1 and ATR inhibition has been shown to sensitize cancer cells to other treatments, making combination therapies a promising strategy.

Differentiated and Specific MOA:

• ORIC-101 and ORIC-591 have unique mechanisms of action (MOA) compared to other DNA damage repair inhibitors.
• They specifically target the WEE1 and ATR kinases, respectively, which are involved in distinct pathways of DNA damage response.

Strong Preclinical and Early Clinical Data:

• Oric's product candidates have demonstrated significant antitumor activity in preclinical models and early clinical trials.
• ORIC-101 and ORIC-591 have shown promising efficacy and safety profiles in patients with advanced cancers.

Pipeline of Promising Candidates:

• In addition to ORIC-101 and ORIC-591, Oric has a pipeline of other preclinical candidates targeting different genetic alterations and DNA damage repair pathways.
• This pipeline provides the company with a robust portfolio of potential therapies for precision oncology.

Experienced Leadership and Scientific Team:

• Oric is led by a team of experienced executives and scientists with a proven track record in oncology drug development.
• The company's scientific team has deep expertise in DNA damage repair and targeted therapies.

Value Creation for Patients and Shareholders:

• By developing innovative and targeted therapies, Oric aims to address the unmet medical needs of cancer patients.
• The company's potential to deliver meaningful clinical benefits has the potential to create significant value for patients and its shareholders.

Oric Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of cancer therapeutics. The company's lead product candidate, ORIC-101, is a small molecule inhibitor of CDK9, a key regulator of gene expression. ORIC-101 is currently being evaluated in a Phase 2 clinical trial for the treatment of acute myeloid leukemia (AML).

Oric Pharmaceuticals is a relatively young company, having been founded in 2014. The company has a small team of approximately 50 employees. Oric Pharmaceuticals has raised approximately $100 million in funding to date.

The company's lead product candidate, ORIC-101, is a promising new therapy for AML. AML is a type of blood cancer that is characterized by the rapid growth of abnormal white blood cells. AML is a difficult-to-treat cancer, and the prognosis for patients is often poor. ORIC-101 has shown promising results in early clinical trials, and the company is currently conducting a Phase 2 clinical trial to evaluate the efficacy and safety of the drug in patients with AML.

Oric Pharmaceuticals is a high-risk, high-reward investment. The company's lead product candidate is still in early clinical development, and there is no guarantee that it will be successful. However, if ORIC-101 is successful, it could be a major new therapy for AML and could generate significant revenue for the company.

Risks:

• Clinical trial risk: ORIC-101 is still in early clinical development, and there is no guarantee that it will be successful. The drug could fail to show efficacy in clinical trials, or it could have unacceptable side effects.
• Regulatory risk: Oric Pharmaceuticals will need to obtain regulatory approval from the FDA before ORIC-101 can be marketed in the United States. The FDA could delay or even deny approval of the drug if it has concerns about its safety or efficacy.
• Competition risk: Oric Pharmaceuticals faces competition from other companies that are developing CDK9 inhibitors. If another company's CDK9 inhibitor is approved before ORIC-101, it could limit the commercial potential of ORIC-101.
• Financial risk: Oric Pharmaceuticals is a small company with limited financial resources. The company may need to raise additional capital to fund its clinical trials and other operations. If the company is unable to raise additional capital, it could delay or even halt the development of ORIC-101.